(Q43253098)

17 November 2017

title

Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension (English)

1 reference

17 November 2017

A Sato

1

1 reference

17 November 2017

S Fukuda

series ordinal

2

1 reference

17 November 2017

publication date

29 October 2009

1 reference

Journal of Human Hypertension

17 November 2017

published in

1 reference

17 November 2017

volume

24

1 reference

17 November 2017

issue

6

1 reference

17 November 2017

page(s)

387-394

1 reference

https://scigraph.springernature.com/pub.10.1038/jhh.2009.81

17 November 2017

exact match

0 references

cites work

Aldosterone, salt and cardiac fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Mineralocorticoids, hypertension, and cardiac fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Efficacy of low-dose spironolactone in subjects with resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Effects of eplerenone versus losartan in patients with low-renin hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

A comparison of the aldosterone-blocking agents eplerenone and spironolactone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-controlled, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Distinguishing the antihypertensive and electrolyte effects of eplerenone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Dose-dependent endothelial cell growth and stiffening by aldosterone: endothelial protection by eplerenone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Can Renin Status Predict the Antihypertensive Efficacy of Eplerenone Add‐On Therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Eplerenone: a review of its use in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Association of adrenal steroids with hypertension and the metabolic syndrome in blacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Prevalence and characteristics of the metabolic syndrome in primary aldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

21 January 2018

Aldosterone in obesity.

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Glucocorticoid receptors in adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

The functional roles of 11 beta-HSD1: vascular tissue, testis and brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

The mineralocorticoid receptor: a journey exploring its diversity and specificity of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Prevalence and lifestyle characteristics of hypertensive patients with metabolic syndrome followed at an outpatient clinic in fukuoka, Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

Aldosterone: a mediator of myocardial necrosis and renal arteriopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

7 January 2021

Effect of spironolactone on blood pressure in subjects with resistant hypertension

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

7 January 2021

Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

7 January 2021

Insulin sensitivity in patients with primary aldosteronism: a follow-up study

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

7 January 2021

Insulin resistance and salt-sensitive hypertension in metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FJHH.2009.81

7 January 2021

Identifiers

DOI

10.1038/JHH.2009.81

1 reference

Dimensions Publication ID

17 November 2017

1052916686

0 references

1 reference